Mikihisa Takano

Last Updated :2023/02/02

Affiliations, Positions
Graduate School of Biomedical and Health Sciences(Pharmaceutical Sciences), Professor
E-mail
takanomhiroshima-u.ac.jp
Other Contact Details
"1-2-3 KASUMI, MINAMI-KU, HIROSHIMA 734-8553", Japan
TEL : (+81)82-257-5315 FAX : (+81)82-257-5319
Self-introduction
Pharmaceutics is a discipline unique to pharmaceutical sciences, including formulation design, mechanisms governing the fate of administered drugs in the body (ADME), control of drug concentration in the body by pharmacokinetic analysis (administration design), and the relationship between tissue distribution of the drug and drug efficacy/toxicity (side effects). Pharmaceutics plays an important role in a wide range of fields, from drug discovery to the proper use of medicines in clinical practice. In our laboratory, we are conducting a series of basic research on drug transporters, which are the controlling factors of pharmacokinetics, from gene level and protein level analysis to systemic pharmacokinetic analysis. We are also interested in research on the molecular mechanism of tissue and cellular toxicity caused by drugs and how to control it. In the future, we would like to feed back the findings obtained from these studies to drug discovery and clinical practice.

Basic Information

Academic Degrees

  • Doctor of Pharmaceutical Sciences, Kyoto University
  • Master of Pharmaceutical Science, Kyoto University

Educational Activity

  • [Bachelor Degree Program] School of Pharmaceutical Sciences : Program of Pharmaceutical Sciences : Pharmaceutical Sciences
  • [Bachelor Degree Program] School of Pharmaceutical Sciences : Program of Medicinal Sciences : Medicinal Sciences
  • [Master's Program] Graduate School of Biomedical and Health Sciences : Division of Integrated Health Sciences : Program of Medicinal Sciences
  • [Doctoral Program] Graduate School of Biomedical and Health Sciences : Division of Integrated Health Sciences : Program of Medicinal Sciences

Research Fields

  • Medicine,dentistry, and pharmacy;Pharmacy;Medical pharmacy

Research Keywords

  • biopharmaceutics
  • pharmacokinetics
  • membrane transport
  • transporter
  • endocytosis
  • organ/cell toxicity of drugs

Affiliated Academic Societies

  • The Pharmaceutical Society of Japan, 1980
  • The Japanese Society for the Study of Xenobiotics, 1997
  • The Academy of Pharmaceutical Science and Technology, Japan, 2000
  • The Membrane Society of Japan, 1981
  • Japanese Society of Pharmaceutical Health Care and Sciences, 1999
  • International Society for the Study of Xenobiotics, 1990

Educational Activity

Course in Charge

  1. 2022, Undergraduate Education, 3Term, Biopharmaceutics
  2. 2022, Undergraduate Education, First Semester, Practice of Drug Delivery System
  3. 2022, Undergraduate Education, 1Term, Pharmacokinetics
  4. 2022, Undergraduate Education, Intensive, Pharmacokinetics
  5. 2022, Undergraduate Education, 4Term, Industrial Pharmaceutics
  6. 2022, Undergraduate Education, 3Term, Japanese Pharmacopoeia
  7. 2022, Undergraduate Education, First Semester, Practice of Pharmaceutics
  8. 2022, Undergraduate Education, Year, Special laboratory Works in Pharmaceutical Sciences I
  9. 2022, Undergraduate Education, Year, Special laboratory Works in Pharmaceutical Sciences II
  10. 2022, Undergraduate Education, Second Semester, Special laboratory Works in Pharmaceutical Sciences III
  11. 2022, Undergraduate Education, Year, Special laboratory Works in Clinical Pharmacy I
  12. 2022, Undergraduate Education, Year, Special laboratory Works in Clinical Pharmacy II
  13. 2022, Undergraduate Education, Year, Special laboratory Works in Clinical Pharmacy III
  14. 2022, Graduate Education (Master's Program) , First Semester, Lecture on Medicinal Science
  15. 2022, Graduate Education (Doctoral Program) , First Semester, Advanced Lecture on Medicinal Science
  16. 2022, Graduate Education (Master's Program) , 3Term, Lecture on Biopharmaceutics
  17. 2022, Graduate Education (Master's Program) , First Semester, Seminar on Biopharmaceutics
  18. 2022, Graduate Education (Master's Program) , Second Semester, Seminar on Biopharmaceutics
  19. 2022, Graduate Education (Master's Program) , First Semester, Research on Biopharmaceutics
  20. 2022, Graduate Education (Master's Program) , Second Semester, Research on Biopharmaceutics
  21. 2022, Graduate Education (Doctoral Program) , First Semester, Advanced Seminar on Biopharmaceutics
  22. 2022, Graduate Education (Doctoral Program) , Second Semester, Advanced Seminar on Biopharmaceutics
  23. 2022, Graduate Education (Doctoral Program) , First Semester, Advanced Research on Biopharmaceutics
  24. 2022, Graduate Education (Doctoral Program) , Second Semester, Advanced Research on Biopharmaceutics
  25. 2022, Graduate Education (Master's Program) , First Semester, Seminar on Drug Delivery Sciences
  26. 2022, Graduate Education (Master's Program) , Second Semester, Seminar on Drug Delivery Sciences
  27. 2022, Graduate Education (Doctoral Program) , Second Semester, Advanced Research on Biopharmaceutics

Research Activities

Academic Papers

  1. A Liquid Chromatography-Mass Spectrometry Method to Study the Interaction between Membrane Proteins and Low-Molecular-Weight Compound Mixtures, MOLECULES, 27(15), 202208
  2. Preventive approach against drug-induced pulmonary fibrosis through the suppression of epithelial-mesenchymal transition, BIOCELL, 46(8), 1861-1865, 2022
  3. Effect of Corticosteroids on Peptide Transporter 2 Function and Induction of Innate Immune Response by Bacterial Peptides in Alveolar Epithelial Cells, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 45(2), 213-219, 202202
  4. Investigation of the role and quantitative impact of breast cancer resistance protein on drug distribution into brain and CSF in rats, DRUG METABOLISM AND PHARMACOKINETICS, 42, 202202
  5. Direct N-1-Selective Alkylation of Hydantoins Using Potassium Bases, CHEMICAL & PHARMACEUTICAL BULLETIN, 69(4), 407-410, 20210401
  6. Differential mechanisms underlying methotrexate-induced cell death and epithelial-mesenchymal transition in A549 cells, TOXICOLOGICAL RESEARCH, 37(3), 293-300, 202107
  7. Functional expression of equilibrative and concentrative nucleoside transporters in alveolar epithelial cells, PHARMAZIE, 76(9), 416-421, 202109
  8. Evaluation on epithelial-mesenchymal state and microRNAs focusing on isolated alveolar epithelial cells from bleomycin injured rat lung, TOXICOLOGY, 461, 202109
  9. Characterization of miR-34a-Induced Epithelial-Mesenchymal Transition in Non-Small Lung Cancer Cells Focusing on p53, BIOMOLECULES, 11(12), 202112
  10. Effect of transforming growth factor-beta 1 on functional expression of monocarboxylate transporter 1 in alveolar epithelial A549 cells, NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 393(5), 889-896, 202005
  11. Suppression of P-glycoprotein by cigarette smoke extract in human lung-derived A549/P-gp cells, DRUG METABOLISM AND PHARMACOKINETICS, 35(2), 214-219, 202004
  12. Role of plasminogen activator inhibitor-1 in methotrexate-induced epithelial-mesenchymal transition in alveolar epithelial A549 cells, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 525(3), 543-548, 20200507
  13. Transport of ribavirin in human myelogenous leukemia cell line K562, PHARMAZIE, 75(7), 329-334, 202007
  14. Suppressive effect of quercetin against bleomycin-induced epithelial-mesenchymal transition in alveolar epithelial cells, DRUG METABOLISM AND PHARMACOKINETICS, 35(6), 522-526, 202012
  15. miR-484: A Possible Indicator of Drug-Induced Pulmonary Fibrosis, JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 23, 486-495, 20201128
  16. Reduced folate carrier-mediated methotrexate transport in human distal lung epithelial NCl-H441 cells, JOURNAL OF PHARMACY AND PHARMACOLOGY, 71(2), 167-175, 201902
  17. Role of peptide transporter 2 and MAPK signaling pathways in the innate immune response induced by bacterial peptides in alveolar epithelial cells, LIFE SCIENCES, 229, 173-179, 20190715
  18. Association of cell cycle arrest with anticancer drug-induced epithelial-mesenchymal transition in alveolar epithelial cells, TOXICOLOGY, 424, 20190801
  19. Anticancer Drug-Induced Epithelial-Mesenchymal Transition via p53/miR-34a axis in A549/ABCA3 Cells, JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 22, 516-524, 20191007
  20. Investigation on inhibitory effect of folic acid on methotrexate-induced epithelial-mesenchymal transition focusing on dihydrofolate reductase, DRUG METABOLISM AND PHARMACOKINETICS, 34(6), 396-399, 201912
  21. Folic acid prevents methotrexate-induced epithelial-mesenchymal transition via suppression of secreted factors from the human alveolar epithelial cell line A549, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 497(1), 457-463, 2018
  22. Transport of AOPP-Albumin into Human Alveolar Epithelial A549 Cells, JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 21, 247-255, 2018
  23. P-gp modulating effect of Azadirachta indica extract in multidrug-resistant cancer cell lines, PHARMAZIE, 73(2), 104-109, 2018
  24. Reduced folate carrier-mediated methotrexate transport in human distal lung epithelial NCl-H441 cells, JOURNAL OF PHARMACY AND PHARMACOLOGY, in press, 2018
  25. Functional expression of breast cancer resistance protein and cholesterol effect in human erythrocyte membranes, PHARMAZIE, in press, 2018
  26. Functional expression of breast cancer resistance protein and cholesterol effect in human erythrocyte membranes, PHARMAZIE, 73(12), 700-705, 201812
  27. Cobalt Chloride Induces Expression and Function of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Renal Proximal Tubular Epithelial Cell Line HK-2, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 40(1), 82-87, 2017
  28. Effect of Curcuma comosa extracts on the functions of peptide transporter and P-glycoprotein in intestinal epithelial cells, PHARMAZIE, 72(2), 123-127, 2017
  29. Effect of COA-Cl on transforming growth factor-beta 1-induced epithelialemesenchymal transition in RLE/Abca3 cells, DRUG METABOLISM AND PHARMACOKINETICS, 32(4), 224-227, 2017
  30. Nicotine transport in lung and non-lung epithelial cells, LIFE SCIENCES, 188, 76-82, 2017
  31. Current Progress Toward a Better Understanding of Drug Disposition Within the Lungs: Summary Proceedings of the First Workshop on Drug Transporters in the Lungs, JOURNAL OF PHARMACEUTICAL SCIENCES, 106(9), 2234-2244, 2017
  32. Role of miR-34a in TGF-beta 1-and Drug-Induced Epithelial-Mesenchymal Transition in Alveolar Type II Epithelial Cells, JOURNAL OF PHARMACEUTICAL SCIENCES, 106(9), 2868-2872, 2017
  33. Transport Mechanism of Nicotine in Primary Cultured Alveolar Epithelial Cells, JOURNAL OF PHARMACEUTICAL SCIENCES, 105(2), 982-988, 2016
  34. Methotrexate-Induced Epithelial-Mesenchymal Transition in the Alveolar Epithelial Cell Line A549, LUNG, 194(6), 923-930, 2016
  35. Effect of cigarette smoke extract on P-glycoprotein function in primary cultured and newly developed alveolar epithelial cells, DRUG METABOLISM AND PHARMACOKINETICS, 31(6), 417-424, 2016
  36. Receptor-mediated endocytosis of macromolecules and strategy to enhance their transport in alveolar epithelial cells, EXPERT OPINION ON DRUG DELIVERY, 12(5), 813-825, 2015
  37. Cisplatin resistance in human lung cancer cells is linked with dysregulation of cell cycle associated proteins, LIFE SCIENCES, 124, 31-40, 2015
  38. Transport Across the Cell Membrane and Its Regulation by Vesicular Transport, 40(1), 21-28, 2015
  39. Analysis of TGF-beta 1-and drug-induced epithelial-mesenchymal transition in cultured alveolar epithelial cell line RLE/Abca3, DRUG METABOLISM AND PHARMACOKINETICS, 30(1), 111-118, 2015
  40. Methotrexate influx via folate transporters into alveolar epithelial cell line A549, DRUG METABOLISM AND PHARMACOKINETICS, 30(4), 276-281, 2015
  41. Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small cell lung cancer: Evaluation of drug-drug interaction, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 76(4), 713-721, 2015
  42. Functional expression of PEPT2 in the human distal lung epithelial cell line NCl-H441, PHARMACEUTICAL RESEARCH, 32(12), 3916-3926, 2015
  43. Development of a novel stop solution for membrane transport study, MEMBRANE, 40(5), 296-303, 2015
  44. Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 76(4), 713-721, 2015
  45. Functional Expression of PEPT2 in the Human Distal Lung Epithelial Cell Line NCl-H441, PHARMACEUTICAL RESEARCH, 32(12), 3916-3926, 2015
  46. Entry of aminoglycosides into renal tubular epithelial cells via endocytosis-dependent and endocytosis-independent pathways, BIOCHEMICAL PHARMACOLOGY, 90(4), 331-337, 2014
  47. Folic acid-modified methotrexate-conjugated PEGylated poly(epsilon-caprolactone) nanoparticles for targeted delivery, JOURNAL OF NANOPARTICLE RESEARCH, 16(2), 2014
  48. Modulation of P-glycoprotein function and multidrug resistance in cancer cells by Thai plant extracts, PHARMAZIE, 69(11), 823-828, 2014
  49. DSE-FRET: A new anticancer drug screening assay for DNA binding proteins, CANCER SCIENCE, 105(7), 870-874, 2014
  50. Fatty acid-bearing albumin but not fatty acid-depleted albumin induces HIF-1 activation in human renal proximal tubular epithelial cell line HK-2, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 450(1), 476-481, 2014
  51. Development of membrane sciences based on mutual interaction between biomembrane and artificial membrane research, 38(4), 20130701
  52. Population Pharmacokinetic/Pharmacodynamic Analysis of the DPP-4 Inhibitor Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus, JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 16(5), 708-721, 2013
  53. For the Understanding and Control of Drug Transport in Cells and Tissues, 73(4), 223-228, 20130701
  54. Albumin overload induces expression of hypoxia-inducible factor 1 alpha and its target genes in HK-2 human renal proximal tubular cell line, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 434(3), 670-675, 2013
  55. Characterization of Protamine Uptake by Opossum Kidney Epithelial Cells, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 36(12), 1942-1949, 2013
  56. Effect of protamine on the accumulation of gentamicin in opossum kidney epithelial cells, JOURNAL OF PHARMACY AND PHARMACOLOGY, 65(3), 441-446, 2013
  57. Enhancing Effect of Poly(amino acid)s on Albumin Uptake in Human Lung Epithelial A549 Cells, DRUG METABOLISM AND PHARMACOKINETICS, 28(6), 497-503, 2013
  58. Expression and function of PEPT2 during transdifferentiation of alveolar epithelial cells, LIFE SCIENCES, 93(17), 630-636, 2013
  59. Flow Cytometry Analysis of Cancer Cell Death Induced by the Extract of Thai Plant Ellipeiopsis cherrevensis, DRUG METABOLISM AND PHARMACOKINETICS, 28(2), 159-163, 2013
  60. Transport of biguanides by human organic cation transporter OCT2, BIOMEDICINE & PHARMACOTHERAPY, 67(5), 425-430, 2013
  61. Drug metabolite heterogeneity in cultured single cells profiled by pico-trapping direct mass spectrometry, NANOMEDICINE, 7(9), 1365-1374, 2012
  62. Effect of Cigarette Smoke Extract on Insulin Transport in Alveolar Epithelial Cell Line A549, LUNG, 190(6), 651-659, 2012
  63. Endocytic Uptake of FITC-albumin by Human Alveolar Epithelial Cell Line A549, DRUG METABOLISM AND PHARMACOKINETICS, 27(3), 336-343, 2012
  64. Enhancement Effect of Poly(amino acid)s on Insulin Uptake in Alveolar Epithelial Cells, DRUG METABOLISM AND PHARMACOKINETICS, 27(6), 570-578, 2012
  65. Gadolinium modulates gentamicin uptake via an endocytosis-independent pathway in HK-2 human renal proximal tubular cell line, European Journal of Pharmacology, 684(1), 146-153, 2012
  66. Nanoparticulation of probucol, a poorly water-soluble drug, using a novel wet-milling process to improve in vitro dissolution and in vivo oral absorption, DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 38(8), 1015-1023, 2012
  67. PHENOTYPICAL CHANGES OF RLE-6TN ALVEOLAR EPITHELIAL CELL LINE BY TRANSFECTION WITH ABCA3 GENE, DRUG METABOLISM REVIEWS, 44, 90-90, 2012
  68. Megalin/Cubilin-mediated Uptake of FITC-labeled IgG by OK Kidney Epithelial Cells, DRUG METABOLISM AND PHARMACOKINETICS, 26(5), 474-485, 2011
  69. Transport of Proteins and Peptides and its Regulation in Alveolar Epithelial Cells, MEMBRANE, 36(4), 145-153, 20110701
  70. Accumulation and Photodynamic Activity of Chlorin e6 in Cisplatin-Resistant Human Lung Cancer Cells, JOURNAL OF PHARMACEUTICAL SCIENCES, 100(7), 3010-3017, 2011
  71. Mechanism underlying insulin uptake in alveolar epithelial cell line RLE-6TN, EUROPEAN JOURNAL OF PHARMACOLOGY, 672(1-3), 62-69, 2011
  72. Effect of Thai Plant Extracts on P-glycoprotein Function and Viability in Paclitaxel-Resistant HepG2 Cells, DRUG METABOLISM AND PHARMACOKINETICS, 25(2), 155-162, 2010
  73. Transport Characteristics of Ribavirin in Human Erythrocyte Membrane Vesicles, Membrane, 35(6), 297-304, 20101101
  74. Human Erythrocyte Nucleoside Transporter ENT1 Functions at Ice-cold Temperatures, 25(4), 351-360, 20100825
  75. Evaluation of In Vitro Dissolution and In Vivo Oral Absorption of Drug Nanopowders Prepared by Novel Wet-Milling Equipment, CURRENT NANOSCIENCE, 6(6), 571-576, 2010
  76. Function and Expression of ATP-Binding Cassette Transporters in Cultured Human Y79 Retinoblastoma Cells, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 33(3), 504-511, 2010
  77. Human transporters that function at ice-cold temperature - Important notice for transporter research -, DRUG METABOLISM REVIEWS, 42, 294-295, 2010
  78. Molecular-targeted approaches to reduce renal accumulation of nephrotoxic drugs, EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 6(9), 1125-1138, 2010
  79. Pharmacokinetic/Pharmacodynamic Modeling and Simulation to Determine Effective Dosage Regimens for Doripenem, JOURNAL OF PHARMACEUTICAL SCIENCES, 99(5), 2483-2491, 2010
  80. CYTOTOXIC AND P-GLYCOPROTEIN MODULATING EFFECTS OF THAI PLANT EXTRACTS IN CANCER CELLS, Abstracts of JSSX meeting, 25, 146-146, 2010
  81. TRANSPORT OF IMMUNOGLOBULIN G IN CULTURED KIDNEY EPITHELIAL CELLS, Abstracts of JSSX meeting, 25(0), 82-82, 2010
  82. Effect of ursodeoxycholic acid treatment on the expression and function of multidrug resistance-associated protein 2 in rat intestine., J. Pharm. Sci., 98(8), 2822-2831, 20090801
  83. Paclitaxel-resistance Conferred by Altered Expression of Efflux and Influx Transporters for Paclitaxel in the Human Hepatoma Cell Line, HepG2, DRUG METABOLISM AND PHARMACOKINETICS, 24(5), 418-427, 2009
  84. Effects of endocytosis inhibitors on internalization of human IgG by Caco-2 human intestinal epithelial cells, Life Sciences, 85(23), 800-807, 20091216
  85. Paclitaxel-resistance Conferred by Altered Expression of Efflux and Influx Transporters for Paclitaxel in the Human Hepatoma Cell Line, HepG2, Drug Metab. Pharmacokinet., 24(5), 418-427, 20091025
  86. Transport Characteristics of Multidrug Resistance-associated Protein 5 in Human Erythrocyte Membranes, Membrane, 34(3), 152-158, 20090501
  87. Effect of PEGylation of N-WASP181-200 on the Inhibitory Potency for Renal Aminoglycoside Accumulation, BIOCONJUGATE CHEMISTRY, 20(8), 1553-1558, 2009
  88. Effect of Thai Plant Extracts on P-Glycoprotein Function and Cell Viability in HepG2 and Paclitaxel-Resistant HepG2 Cells, DRUG METABOLISM REVIEWS, 41, 62-62, 2009
  89. Mechanism of Insulin Uptake in Rat Alveolar Type II and Type I-Like Epithelial Cells, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 32(10), 1765-1769, 2009
  90. Nanoparticulation of Poorly Water Soluble Drugs Using a Wet-Mill Process and Physicochemical Properties of the Nanopowders, CHEMICAL & PHARMACEUTICAL BULLETIN, 57(10), 1050-1057, 2009
  91. INFLUENCE OF PEGYLATED N-WASP181-200 ON RENAL ACCUMULATION OF AMINOGLYCOSIDES, Abstracts of JSSX meeting, 24, 158-158, 2009
  92. INTERNALIZATION MECHANISM OF HUMAN IMMUNOGLOBULIN G IN CACO-2 HUMAN INTESTINAL EPITHELIAL CELLS, Abstracts of JSSX meeting, 24, 164-164, 2009
  93. IMPROVEMENT OF THE DISSOLUTION RATE AND ORAL ABSORPTION OF PROBUCOL, A POORLY WATER-SOLUBLE DRUG, BY WET-MILLING PROCESS, Abstracts of JSSX meeting, 24, 249-249, 2009
  94. Live single-cell video-mass spectrometry for cellular and subcellular molecular detection and cell classification, JOURNAL OF MASS SPECTROMETRY, 43(12), 1692-1700, 2008
  95. Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents., Antimicrob. Agents Chemother., 52(9), 3229-3236, 20080901
  96. Transport of prostaglandin E1 across rat erythrocyte membrane., Biol Pharm Bull, 31(6), 1288-1291, 20080601
  97. Comparison of albumin uptake in rat alveolar type II and type I-like epithelial cells in primary culture., Pharm. Res., 25(4), 913-922, 20080401
  98. Clinical Effects of Neo-Burow's Solution and Important Points in its Preparation, Japanese journal of pharmaceutical health care and sciences, 34(10), 951-955, 20081010
  99. Transport of Prostaglandin E_1 across Rat Erythrocyte Membrane(Biopharmacy), Biological & pharmaceutical bulletin, 31(6), 1288-1291, 20080601
  100. Development of new pharmacotherapy and diagnosis based on membrane transporter research, 33(3), 20080501
  101. Pharmacokinetics and Pharmacodynamics : Where are they going?, Drug Metabolism and Pharmacokinetics, 23(2), 85-86, 20080425
  102. Influx and efflux transporters in the intestine, Cell technology., 27(8), 790-795, 200808
  103. Intestinal efflux transporters and drug absorption, EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 4(7), 923-939, 2008
  104. Low-Affinity Transport of FITC-Albumin in Alveolar Type II Epithelial Cell Line RLE-6TN, DRUG METABOLISM AND PHARMACOKINETICS, 23(5), 318-327, 2008
  105. Pharmacokinetic-pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic model, JOURNAL OF PHARMACEUTICAL SCIENCES, 97(9), 4108-4117, 2008
  106. Prediction of human antimicrobial effective target by in vitro pharmacokinetic/pharmacodynamic modeling for bactericidal effect, YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 128, 78-78, 2008
  107. Transport of ribavirin and uridine in human erythrocytes and erythrocyte membrane vesicles, YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 128, 79-79, 2008
  108. MECHANISM OF INSULIN UPTAKE IN RAT ALVEOLAR TYPE II AND TYPE I-LIKE EPITHELIAL CELLS IN PRIMARY CULTURE, Abstracts of JSSX meeting, 23, 128-128, 2008
  109. NON-LINEAR PHARMACOKINETICS IN ANIMALS: CLARIFICATION OF MECHANISM AND EXTRAPOLATION TO HUMANS, Abstracts of JSSX meeting, 23, 212-212, 2008
  110. MECHANISM OF INSULIN UPTAKE AND EFFECT OF POLY(AMINO ACID)S IN RAT ALVEOLAR TYPE II EPITHELIAL CELL LINE, RLE-6TN, Abstracts of JSSX meeting, 23, 182-182, 2008
  111. EXPRESSION AND FUNCTION OF P-GLYCORPOTEIN AND MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS IN HUMAN RETINOBLASTOMA Y79 CELL LINE, Abstracts of JSSX meeting, 23, 113-113, 2008
  112. Role of intestinal efflux transporters in the intestinal absorption of methotrexate in rats., J Pharm Pharmacol, 59(9), 1263-1270, 20070901
  113. Modulation of function of multidrug resistance associated-proteins by Kaempferia parviflora extracts and their components., Eur J Pharmacol, 566(1-3), 67-74, 20070701
  114. Site-specific bidirectional efflux of 2,4-dinitrophenyl-S-glutathione, a substrate of multidrug resistance-associated proteins, in rat intestine and Caco-2 cells., J Pharm Pharmacol, 59(4), 513-520, 20070401
  115. Effects of Kaempferia parviflora extracts and their flavone constituents on P-glycoprotein function., J Pharm Sci, 96(1), 223-233, 20070101
  116. ENDOCYTOSIS OF ALBUMIN AND INSULIN IN ALVEOLAR TYPE II EPITHELIAL CELL LINE RLE-6TN, DRUG METABOLISM REVIEWS, 39, 162-163, 2007
  117. Transcytosis of IgG in human intestinal epithelial Caco-2 cells, YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 127, 165-166, 2007
  118. Clathrin-mediated endocytosis of FITC-albumin in alveolar type II epithelial cell line RLE-6TN, Annual report of the Faculty of Pharmacy & Pharmaceutical Sciences, Fukuyama University, 25, 93-94, 2007
  119. Function of multidrug resistance-associated protein 2 in acute hepatic failure rats., Eur J Pharmacol, 546(1-3), 152-160, 20060901
  120. Interaction of valproic acid and carbapenem antibiotics with multidrug resistance-associated proteins in rat erythrocyte membranes., Epilepsy Res, 71(1), 76-87, 20060901
  121. Characterization of prostaglandin E1 transport in rat renal brush-border membrane., Drug Metab Pharmacokinet, 21(3), 186-193, 20060601
  122. Clathrin-mediated endocytosis of FITC-albumin in alveolar type II epithelial cell line RLE-6TN, AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 290(5), L946-L955, 20060501
  123. Inhibition of gentamicin binding to rat renal brush-border membrane by megalin ligands and basic peptides., J Control Release, 112(1), 43-50, 20060501
  124. Inhibitory effect of Thai plant extracts on P-glycoprotein mediated efflux, Phytother Res., 20, 79-81, 20060401
  125. Characterization of Prostaglandin E_1 Transport in Rat Renal Brush-border Membrane, Drug Metabolism and Pharmacokinetics, 21(3), 186-193, 20060630
  126. CHARACTERIZATION OF CELLULAR UPTAKE OF THE BASIC PEPTIDE N-WASP181-200 THAT INHIBITS RENAL ACCUMULATION OF GENTAMICIN, Abstracts of JSSX meeting, 21, 208-208, 2006
  127. EFFECT OF URSODEOXYCHOLATE ON THE FUNCTION OF INTESTINAL EFFLUX TRANSPORTERS AND CYP3A IN RATS, Abstracts of JSSX meeting, 21, 210-210, 2006
  128. Pharmacokinetic interaction on valproic acid and recurrence of epileptic seizures during chemotherapy in an epileptic patient, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 59(5), 593-597, 2005
  129. Characterization of prostaglandin E1 transport by rat renal cortical slices, Eur. J. Pharmacol., 525(1-3), 128-134, 20051101
  130. Increased erythrocyte distribution of valproic acid in pharmacokinetic interaction with carbapenem antibiotics in rat and human, J. Pharm. Sci., 94(8), 1685-1693, 20050801
  131. Modulation of intestinal transport of 2,4-dinitrophenyl-S-glutathione, a multidrug resistance-associated protein 2 substrate, by bilirubin treatment in rats, JOURNAL OF PHARMACY AND PHARMACOLOGY, 57(5), 579-585, 20050501
  132. Expression and function of efflux drug transporters in the intestine, Pharmacology and Therapeutics, 109, 137-161, 20050401
  133. Role of organic anion transporting polypeptide 2 in pharmacokinetics of digoxin and beta-methyldigoxin in rats., J Pharm Sci, 94(6), 1196-1203, 20050101
  134. Transport of prostaglandin E1 across the blood-brain barrier in rats, J. Pharm. Pharmacol., 57(1), 61-66, 20050101
  135. Molecular mechanism for the inhibitory effect of basic peptides on aminoglycoside binding to renal brush-border membrane and cellular uptake, YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 125, 42-43, 2005
  136. Differences in Burow's Solution (Aluminum Acetate Solution) Between Japan and Other Countries : How Should We Prepare Burow's Solution?, Japanese journal of pharmaceutical health care and sciences, 31(9), 749-754, 20050910
  137. Pharmaceutical and pharmacological evaluation of Burow’s solution (alminium acetate solution), a hospital preparation, and development of its rapid preparation method, Yakugaku Zasshi, 124(11), 833-840, 20041101
  138. Employing renal Function in Determining Ribavirin Dosages for Chronic Hepatitis c Patients to Help Ensure Safter Treatment, Jpn. J. Pharm. Health Care Sci., 30(9), 567-573, 20040901
  139. Effect of Neonatal Exposure of 17beta-Estradiol and Tamoxifen on Hepatic CYP3A Activity at Developmental Periods in Rats, Drug Metab Pharmacokin, 19(2), 96-102, 20040401
  140. Employing renal function in determining rivabirin dosages for chronic hepatitis C patients to help ensure safer treatment, Jpn. J. Pharm. Health Care Sci., 30(9), 567-573, 20040401
  141. Segment-selective absorption of lysozyme in the intestine, Eur. J. Pharmacol., 502, 149-155, 20040401
  142. Targeted prevention of renal accumulation and toxicity of gentamicin by aminoglycoside binding receptor antagonists, J. Contl. Rel., 95(3), 423-433, 20040301
  143. Dosage Adjustment of Ribavirin based on Renal Function in Japanese Patients with Chronic Hepatitis C, Therap Drug Monit, 26(1), 9-15, 20040101
  144. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity, Drug Metab Pharmacokin, 19(3), 159-170, 20040101
  145. Effect of Neonatal Exposure of 17β-Estradiol and Tamoxifen on Hepatic CYP3A Activity at Developmental Periods in Rats, 19(2), 96-102, 20040426
  146. Molecular Aspects of Renal Handling of Aminoglycosides and Strategies for Preventing the Nephrotoxicity, Drug Metabolism and Pharmacokinetics, 19(3), 159-170, 2004
  147. EFFECTS OF N-WASP181-200 AND ITS MUTANT PEPTIDE ON RENAL BINDING AND UPTAKE OF GENTAMICIN, Abstracts of JSSX meeting, 19, 171-171, 2004
  148. Participation of P-glycoprotein in excretion of Parkinson's disease-related neurotoxins from brain, Abstracts of JSSX meeting, 19, 175-175, 2004
  149. Segment-selective absorption of lysozyme in the intestine, Abstracts of JSSX meeting, 19, 53-53, 2004
  150. Differential effect of acute hepatic failure on in-vivo and in-vitro P-glycoprotein functions in the intestine, Pharm. Res., 20(5), 765-771, 20030401
  151. Role of P-glycoprotein in pharmacokinetics and drug interactions of digoxin and beta-methyldigoxin in rats, J. Pharm. Sci., 92(7), 1455-1463, 20030401
  152. Cisplatin-induced inhibition of receptor-mediated endocytosis of protein in the kidney., Kidney Int., 62(5), 1707-1717, 20021101
  153. Effect of gentamicin on pharmacokinetics of lysozyme in rat: interaction between megalin substrates in the kidney., J. Pharm. Pharmacol., 54(11), 1491-1496, 20021101
  154. Possible mechanism for pharmacokinetic interaction between lidocaine and mexiletine, Clin. Pharmacol. Ther, 71(5), 389-397, 20020501
  155. Interaction of endogenous compounds in human and rat urine with P-glycoprotein, Drug Metabol. Pharmacokin., 17(3), 245-252, 20020401
  156. Renal disposition of a furan dicarboxylic acid and other uremic toxins in the rat, J. Pharmacol. Exp. Ther., 303(2), 880-887, 20020401
  157. Factors affecting the expression and function of P-glycoprotein in rats: drug treatments and disease states., Pharmazie, 57, 102-107, 20020201
  158. Promotion of Clinical Pharmacy Research Based on Collaboration between University and Hospital or Community Pharmacy : Questionnaire Survey of Present Situations and Needs, Japanese journal of pharmaceutical health care and sciences, 28(5), 484-488, 20021010
  159. Role of megalin in renal handling of aminoglycosides, AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 281(2), F337-F344, 20010801
  160. Expression and function of P-glycoprotein in rats with carbon tetrachloride-induced acute hepatic failure, J. Pharm. Pharmacol., 53(6), 873-881, 20010601
  161. Expression of chloride channel, ClC-5, and its role in receptor-mediated endocytosis of albumin in OK cells, Biochem. Biophys. Res. Commun., 282(1), 212-218, 20010301
  162. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone, Drug Metab. Dispos., 29(2), 145-151, 20010201
  163. Receptor-mediated Endocytosis in Renal Tubules and its Dysfunction Induced by Drugs., Drug Metabolism and Pharmacokinetics, 16(1), 38-44, 2001
  164. Effect of cisplatin on H+ transport by H+-ATPase and Na+/H+ exchanger in rat renal brush-border membrane, Life Sci., 67(9), 1047-1058, 20000701
  165. Role of P-glycoprotein in ocular clearance of rhodamine 123 in rabbits, Pharm. Res., 17(4), 479-481, 20000401
  166. Expression and function of P-glycoprotein in rats with glycerol-induced acute renal failure, Eur. J. Pharmacol., 406(3), 453-460, 20000101
  167. MECHANISMS UNDERLYING RENAL TUBULAR ACIDOSIS AND ALBUMINURIA INDUCED BY CISPLATIN, Drug Metabolism and Pharmacokinetics, 15(0), 124-125, 2000
  168. Enhancement of topical delivery of a lipophilic drug from charged multilamellar liposomes, J.Drug Target., 6(6), 405-414, 19990401
  169. Hepatic Metabolic clearance of midazolam, a cytochrome P450 3A substrate, in the presence of ketoconazole in rats, Pharm. Pharmacol. Commun., 5, 529-536, 19990401
  170. In-vivo and in-vitro metabolic clearance of midazolam, a cytochrome P450 3A substrate, by the liver under normal and increased enzyme activity in rats, J. Pharm. Pharmacol., 51(4), 405-410, 19990401
  171. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds, J. Pharmacol. Exp. Ther., 289(1), 149-155, 19990401
  172. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modified enzyme activity in rats, J. Pharm. Pharmacol., 51(1), 67-72, 19990101
  173. Neurotoxic effects of phenytoin on postnatal mouse brain development following neonetal administration, Neurotoxicol. Teratol., 21(1), 21-28, 19990101
  174. Soft X-ray magnetic circular dichroism in La_1-x_Sr_x_MnO_3_ and SrFe_1-x_Co_x_O_3_, Journal of Magnetic Society of Japan, 23, 341-345, 19990101
  175. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells, Eur. J. Pharmacol., 358(3), 289-294, 19981001
  176. Renal excretion of rhodamine 123, a P-glycoprotein, in rats with glycerol -induced acute renal failure, J. Pharm. Pharmacol., 50(10), 1161-1165, 19981001
  177. In-vitro calibration of microdialysis probe by use of endogenous glucose as an internal recovery marker: Measurement of skin distribution of tranilast in rats., J. Pharm. Pharmacol., 50(6), 621-626, 19980601
  178. Efflux of intracellular alpha-ketoglutarate via p-aminohippurate/dicarboxylate exchange in OK kidney epithelial cells., J Pharmacol Exp Ther, 285(2), 422-427, 19980501
  179. Photoemission magnetic circular dichroism study of the ferromagnetic transition-metal oxide SrRuO_3_, Journal of Electron Spectroscopy and Related Phenomena, 92(1-3), 41-44, 19980501
  180. Hepatic clearance of a novel neutrophil elastase inhibitor, ONO-5046, in rats and in the perfused rat liver, J. Pharm. Pharmacol., 50(4), 425-430, 19980401
  181. Hepatic clearance of ONO-5046, a novel neutrophil elastase inhibitor, in rats and in the rat perfused liver., Journal of Pharmacy and Pharmacology, 50(4), 425-430, 19980401
  182. Renal organic anion secretion and alpha-ketoglutarate level in rats with chronic metabolic acidosis, Pharm. Pharmacol. Commun., 4, 301-304, 19980401
  183. Influences of Dosage Regimen and coadministration of low-molecular weight proteins and basic peptides on renal accumulation of arbekacin in mice., J. Antimicrob. Chemother., 61(3), 658-664, 19980301
  184. Inhibition of PAH transport by parathyroid hormone in OK cells: involvement of protein kinase C pathway., Am J Physiol, 273(5 PT 2), F674-F679, 19971101
  185. Regulation of p-aminohippurate transport by protein kinase C in OK kidney epithelial cells., Am J Physiol, 271(2 PT 2), F469-F475, 19960801
  186. Specificity of p-aminohippurate transport system in the OK kidney epithelial cell line., J Pharmacol Exp Ther, 274(3), 1161-1166, 19950901
  187. Transport of Organic Ions in Renal Proximal Tubular Epithelial Cells, MEMBRANE, 20(6), 416-422, 19951101
  188. Identification of Organic Cation Transporter in Rat Renal Brush-Border Membrane by Photoaffinity Labeling, Biological & pharmaceutical bulletin, 18(3), 388-395, 19950315
  189. Transport Mechanisms of Drugs in Renal Tubular Epithelial Cells., Drug Metabolism and Pharmacokinetics, 10(4), 556-565, 1995
  190. Properties of M33 X-8, the nuclear source in the nearby spiral galaxy, Astrophysical Journal Letters, 436(1), L47-L50, 19940601
  191. Differential sensitivity of organic anion transporters in rat renal brush-border membrane to diethyl pyrocarbonate., Biochim Biophys Acta, 1192(2), 190-196, 19940101
  192. Photoemission and X-ray absorption study of La/sub 1-x/Sr/sub x/MnO/sub3/, Jpn. J. Appl. Phys. Suppl. (Japan), 32(suppl.32-3), 258-260, 19930401
  193. Drug-induced nephrotoxicity, Pharma. Medica., 11(7), 63-67, 19930401
  194. Transport Mechanism of Choline in Rat Renal Brush-Border Membrane, Biological & pharmaceutical bulletin, 16(9), 889-894, 19930915
  195. TRANSCELLULAR TRANSPORT OF p-AMINOHIPPURATE, AN ORGANIC ANION, IN CULTURED KIDNEY EPITHELIAL CELLS, Drug Metabolism and Pharmacokinetics, 8(0), 715-718, 1993
  196. Transport of drugs in biological membranes, MEMBRANE, 17(3), 142-152, 19920401
  197. Transport of Drugs in the Plasma Membranes., MEMBRANE, 17(3), 142-152, 1992
  198. Organic cation transport in the renal brush-border and basolateral membranes, Nephrology, 19910401
  199. TRANSPORT MECHANISMS OF BESTATIN IN INTESTINAL AND RENAL BRUSH-BORDER MEMBRANES, Journal of pharmacobio-dynamics, 14(3), 55-60, 199103
  200. TRANSPORT CHARACTERISTICS AND CYTOTOXICITY OF CYCLOSPORIN A IN CULTURED KIDNEY EPITHELIAL CELL LINE (LLC-PK_1), Journal of pharmacobio-dynamics, 13(5), 111-115, 199005
  201. H+ Coupled transport of p.o. cephalosporins via dipeptide carriers in rabbit intestinal brush-border membranes: Difference of transport characteristics between cefixime and cephradine, J. Pharmacol. Exp. Ther., 247(1), 235-241, 19880401
  202. Enhancing mechanism of decanoic acid for the permeation of water-soluble compounds through Caco-2 cell monolayers, Pharm. Sci, 3, 175-178, 19870401
  203. TRANSPORT MECHANISMS OF β-LACTAM ANTIBIOTICS IN INTESTINAL BRUSH-BORDER MEMBRANES, Journal of pharmacobio-dynamics, 10(5), 136-141, 198705
  204. TRANSPORT MECHANISMS OF CATIONIC DRUGS IN RAT RENAL BRUSH-BORDER AND BASOLATERAL MEMBRANES, Journal of pharmacobio-dynamics, 8(5), 110-115, 198505
  205. TRANSPORT OF DRUGS BY PLASMA MEMBRANE VESICLES ISOLATED FROM RAT KIDNEY CORTEX, Journal of pharmacobio-dynamics, 4(2), 15-20, 198102

Invited Lecture, Oral Presentation, Poster Presentation

  1. Relationship between abemaciclib-induced cytotoxicity and epithelial-mesenchymal transition in A549 cells, Sorahito Futatsugi, Ryoko Yumoto, Masashi Kawami, Mikihisa Takano, 35nd JSSX Annual Meeting, 2020/12/01, Without Invitation, English, Virtual meeting
  2. Role of high glucose and advanced glycation end products in inducing epithelial-mesenchymal-transition in alveolar epithelial cells, Miho Izumi, Shunsuke Senoo, Masashi Kawami, Ryoko Yumoto, Mikihisa Takano, 35nd JSSX Annual Meeting, 2020/12/01, Without Invitation, English
  3. In vitro study on secreted factors associated with drug-induced epithelial-mesenchymal transition in A549 cells, Masashi Kawami, Yohei Yamagami, Risako Harada, Takamichi Ojima, Ryoko Yumoto, Mikihisa Takano, The 1st Workshop of The Research Center for Drug Development and Biomarker Discovery, 2019/03/02, Without Invitation, English
  4. Role of transporters related to metabolic changes during epithelial-mesenchymal transition in human alveolar epithelial cell line A549, Mohi Uddin, Ryoko Yumoto, Masashi Kawami, Mikihisa Takano, 2018 International Meeting on 22nd MDO and 33rd JSSX, 2018/10/04, Without Invitation, English, Ishikawa Ongakudo Hall
  5. Role of plasminogen activator inhibitor-1 in methotrexate-induced epithelial-mesenchymal transition in cultured human alveolar epithelial A549 cells, Yohei Yamagami, Ryoko Yumoto, Masashi Kawami, Mikihisa Takano, 2018 International Meeting on 22nd MDO and 33rd JSSX, 2018/10/04, Without Invitation, English, Ishikawa Ongakudo Hall
  6. Search for the compound preventing drug-induced epithelial-mesenchymal transition and its mechanism in alveolar epithelial RLE/Abca3 cells, Shunsuke Senoh, Junya Deguchi, Ryoko Yumoto, Mikihisa Takano, 2018 International Meeting on 22nd MDO and 33rd JSSX, 2018/10/04, Without Invitation, English, Ishikawa Ongakudo Hall
  7. Role of membrane cholesterol in the functions of influx and efflux transporters in human erythrocytes, Makoto Higashi, Hiroki Ito, Ryoko Yumoto, Mikihisa Takano, 2018 International Meeting on 22nd MDO and 33rd JSSX, 2018/10/04, Without Invitation, English, Ishikawa Ongakudo Hall
  8. Study on association of drug-induced cell cycle arrest with epithelial-mesenchymal transition in A549 cells, Masashi Kawami, Risako Harada, Takamichi Ojima, Ryoko Yumoto, Mikihisa Takano, 2018 International Meeting on 22nd MDO and 33rd JSSX, 2018/10/02, Without Invitation, English, Ishikawa Ongakudo Hall
  9. Role of miR-34a and p53 pathway in drug-induced epithelial-mesenchymal transition in alveolar epithelial cells, Ayano Yamamoto, Masashi Kawami, Ryoko Yumoto, Mikihisa Takano, 2018 International Meeting on 22nd MDO and 33rd JSSX, 2018/10/02, Without Invitation, English, Ishikawa Ongakudo Hall
  10. Effect of cigarette smoke extract on the function and expression of P-glycoprotein in human lung-derived A549/P-gp cells and its mechanism, Shuhei Higa, Ryoko Yumoto, Mikihisa Takano, 2018 International Meeting on 22nd MDO and 33rd JSSX, 2018/10/02, Without Invitation, English, Ishikawa Ongakudo Hall
  11. 肺障害性薬物による肺胞上皮細胞の上皮間葉転換とmiRNAの関連解析, 川見昌史、山本彩乃、湯元良子、高野幹久, 日本薬剤学会第33年会, 2018/05/30, Without Invitation, Japanese, 静岡コンベンションセンターグランシップ
  12. Effect of cigarette smoke extract on the function and expression of membrane transporters in alveolar epithelial cells, Mikihisa Takano, The 8th Annual Meet the Experts Transporter conference, 2018/04/26, With Invitation, English, Budapest, Hungary
  13. A novel concept of nicotine transport across the cell membranes in human lung- and non-lung-derived culture cells, Ryoko Yumoto, Hidetaka Kamei, Masashi Kawami, Mikihisa Takano, The 8th Annual Meet the Experts Transporter conference, 2018/04/26, Without Invitation, English, Budapest, Hungary
  14. Modulation of P-glycoprotein function and sensitivity to anticancer drug by Azadirachta indica extract in multidrug resistant cell lines, Masashi Kawami, Yukinori Yamada, Ousanee Issarachot, Varaporn Junyaprasert, Ryoko Yumoto, Mikihisa Takano, 6th Pharmaceutical Sciences World Congress, 2017/05/22, Without Invitation, English, Stockholmsmassan, Stockholm, Sweden
  15. Functional analysis of breast cancer resistant protein, an ATP-binding cassette transporter, in human erythrocyte membranes, 2015/05/14, Without Invitation, Japanese

Awards

  1. 2015/11/13, JSSX Award 2015, The Japanese Society for the Study of Xenobiotics
  2. 2008/10, Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity, 日本薬物動態学会会長, 日本薬物動態学会の学会誌Drug Metabolism and Pharmacokinetics (DMPK)に発表した当研究室の総説論文が、2004年に掲載されたDMPKの総説論文の中で、最も多くの被引用回数取得

External Funds

Acceptance Results of Competitive Funds

  1. KAKENHI(Grant-in-Aid for Scientific Research (B)), 2018, 2021
  2. KAKENHI, 2014, 2016
  3. KAKENHI, 2014, 2017
  4. KAKENHI, Analysis of low temperature tolerance of membrane transporters and development of pan-transporter inhibitors, 2011, 2013
  5. KAKENHI, 2011, 2014
  6. KAKENHI, Establishment of a new alveolar epithelial cell model by gene transfection and its application to the study on drug transport and toxicity in the lungs, 2010, 2013
  7. KAKENHI, Study on the transportsome for ribavirin uptake in human erythrocyte membrane, 2009, 2011
  8. KAKENHI, Pharmacokinetic properties of vitamin-binding proteins and these application to vector for drug delivery, 2007, 2008
  9. KAKENHI, Drug Transport in human erythrocyte membrane and drug interaction/adverse reaction in erythrocyte, 2007, 2008
  10. KAKENHI, Study on the transport of proteins in alveolar type I/II epithelial cells for the development of new pulmonary DDS systems, 2007, 2009
  11. KAKENHI, Search for traditional medicines in Thailand and scientific evaluation of their pharmacological effects, 2007, 2009
  12. KAKENHI, Development of protein drug delivery system from the lung based on ligand recognition mechanisms of the receptors, 2005, 2006
  13. KAKENHI, 2001, 2001
  14. KAKENHI, Studies on the mechanisms underlying renal tubular deficiency due to the lack of the expression and function of CLCN5, a gene responsible for Dent's disease, 2001, 2002
  15. KAKENHI, Search for the new, endogenous compound with multidrug resistance modulating activity and its application to cancer chemotherapy, 1999, 2000
  16. KAKENHI, Effect of endocrine disrupting chemicals on host defense mechanism (transpoter, enzymes), 1999, 2001
  17. KAKENHI, 1997, 1998
  18. KAKENHI, 1996, 1996
  19. KAKENHI, 1994, 1994
  20. KAKENHI, 1994, 1994
  21. KAKENHI, Molecular and Cell Biological Analyzes of Structure and Function of Drug Transporters in the Intestine and Kidney Proximal Tubule, 1994, 1995
  22. KAKENHI, 1993, 1993
  23. KAKENHI, 1993, 1993
  24. KAKENHI, 1992, 1992
  25. KAKENHI, Scientific Basis of Drug Disposition in the Kidney and its Application to Clinical Dosage Regimens., 1991, 1992
  26. KAKENHI, In Vitro New Evaluation Method for the Drug Absorption and Secretion Using Membrane Vesicles, 1989, 1990

Social Activities

Organizing Academic Conferences, etc.

  1. The 141st Annual Meeting of the Pharmaceutical Society of Japan (Hiroshima), 2021/03, 2021/03
  2. 2019/11, 2019/11
  3. 32nd JSSX Annual Meeting in Tokyo, 2017/11, 2017/12
  4. 2016/12, 2016/12
  5. Workshop on Drug Transporters in the Lungs 2016, Organizing Committee Member, 2016/09, 2016/09
  6. 2016/05, 2016/05
  7. 2015/11, 2015/11
  8. 2015/05, 2015/05
  9. 2013/05
  10. 2009/11
  11. 2008/12
  12. 2003/07
  13. 1998/06

History as Peer Reviews of Academic Papers

  1. 2020, Journal of Nutritional Biochemistry, Others, 1
  2. 2020, Experimental Lung Research, Others, 1
  3. 2020, European Journal of Pharmacology, Others, 1
  4. 2020, Pharmacology & Therapeutics, Others, 1
  5. 2019, Journal of Pharmaceutical Sciences, Others, 1
  6. 2019, Journal of Nutritional Biochemistry, Others, 1
  7. 2019, Biological and Pharmaceutical Bulletin, Others, 1
  8. 2019, Pharmaceutical Research, Others, 1
  9. 2019, The Journal of Pharmaceutical Sciences, Editor, Editorial Advisory Board
  10. 2018, The Journal of Pharmaceutical Sciences, Editor, Editorial Advisory Board
  11. 2007, 薬学雑誌, Editor
  12. 2007, Drug Metabol. Pharmacokin., Others
  13. 2007, 薬学雑誌, Editor
  14. 2007, Drug Metab Pharmacokinet, Editor
  15. 2007, Drug Metabol. Pharmacokin., Others
  16. 2007, 薬学雑誌, Editor
  17. 2007, Drug Metabol. Pharmacokin., Others